Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $1.81, $0.29 better than the analyst estimate of $1.52. Revenue for the quarter came in at $622.1 million versus the consensus estimate of $600.97 million.

GUIDANCE:

Neurocrine Biosciences sees FY2024 revenue of $2.3-2.32 billion, versus the consensus of $2.33 billion.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.